Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)-Reference-Cited by-同舟云学术

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

Published:2021-07-01 Issue: Volume: Page:
ISSN:
Container-title:Clinical Trials
language:
Short-container-title:

Author:

Long Georgina V.,Schadendorf Dirk,Vecchio Michele Del,Larkin James,Atkinson Victoria,Schenker Michael,Pigozzo Jacopo,Gogas Helen J.,Dalle Stéphane,Meyer Nicolas,Ascierto Paolo A.,Sandhu Shahneen,Eigentler Thomas,Gutzmer Ralf,Hassel Jessica C.,Robert Caroline,Carlino Matteo,Giacomo Anna Maria Di,Butler Marcus O.,Muñoz-Couselo Eva,Brown Michael P.,Rutkowski Piotr,Haydon Andrew,Grob Jean-Jacques,Schachter Jacob,Queirolo Paola,Menzies Alexander,Re Sandra,Bas Tuba O.,de Pril Veerle,Tenney Daniel,Tang Hao,Weber Jeffrey S.

Publisher

American Association for Cancer Research

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics of Real-World Patients with High-Risk BRAFV600E/K-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program;Cancer Management and Research;2023-11

2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0;Journal for ImmunoTherapy of Cancer;2023-10

3. PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy;European Journal of Surgical Oncology;2023-10

4. Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma;European Journal of Cancer;2023-06

5. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma;Nature Reviews Clinical Oncology;2023-05-05